Through the acquisition, InnoSer International will expand its existing in vitro and in vivo preclinical services portfolio with a wide range of validated models to support preclinical neuroscience research. These in vivo models are supported with strong complementary capabilities such as proprietary behavioral testing, stereotactic surgery, EEG and EMG analysis, bioinformatics and specialized histopathology. Sylics’ operations, based in Bilthoven, will extend to InnoSer’s in vivo facilities in Leiden and the entire Sylics team will be integrated within InnoSer. Sylics’ Chief Executive Officer, Maarten Loos, will lead the newly integrated operations of InnoSer in the Netherlands.
Maarten Loos, Chief Executive Officer of Sylics, comments: “We are looking forward to the collaboration with the expert team at Innoser as it will allow our clients to evaluate their compounds within a wide range of newly integrated models and services. The combined expertise allows for rigorous testing in a range of additional therapeutic areas including, nephrology, immuno-oncology, and cardio-metabolic disease models. We will maintain our shared history of dedication to customer service and continue to serve complex needs within all stages of preclinical drug development”.
Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting preclinical drug development from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug development journey with well-characterized in vitro and in vivo disease models in addition to general drug development services, to uncover valuable insights into the mode of action, pharmacokinetics, safety, and efficacy of investigational compounds.
Sylics offers innovative research solutions for preclinical neuroscience. Sylics specializes in developing and employing customized mouse models and behavioural tests for neurological and psychiatric diseases. Highly efficient, sensitive, and reproducible screening for behavioural deficits is supported by Sylics’ automated screening platform and proprietary analysis software AHCODA™. For more than 15 years, Sylics successfully characterized dozens of novel mouse models, and determined compound efficacy in numerous projects for academia, biotech, food and pharma clients.
For more information, please contact:
Chief Business Officer